Literature DB >> 11105424

Managing the assessment of neonatal jaundice: importance of timing.

V K Bhutani1, L H Johnson.   

Abstract

In view of the limitations in the accurate visual assessment of jaundice and its potential role as a predictive vector for serious neurologic sequelae, we propose that a universal screening of bilirubin be considered concurrent to the routine pre-discharge metabolic screening. Universal bilirubin screening in the term and near-term newborns when plotted on "Hour-specific Bilirubin Nomogram" in lieu of the usual "day-specific" value will predict the high-risk and the low-risk groups and facilitate cost-effective and individualized follow-up of those babies at risk. A percentile based bilirubin nomogram for the first week of age was constructed from hour-specific pre- and post-discharge bilirubin values of 2840 healthy term and near-term babies. The accuracy of the pre-discharge bilirubin values was determined as a predictive vector. Pre-discharge (18-72 hours age), 6.1% of the study population had bilirubin values in the high-risk zone (> 95th percentile). Of these, 39.5% remained in that zone (likelihood ratio ¿LR¿ = 14.08). Pre-discharge, 32.1% of the study population had bilirubin values in the intermediate risk zone (40-75th percentiles). In a clinically significant minority of these babies (6.4%), the post-discharge values moved to the high-risk zone (L-R = 3.2 for the move from the upper-intermediate zone and 0.48 from the lower-intermediate zone). In the remainder 61.8% of the population who were identified to be at low risk, there was no measurable risk for significant hyperbilirubinemia (L-R = 0). The bilirubin nomogram can predict which infant is at high, intermediate, and low risk for subsequent excessive hyperbilirubinemia and allows for the individualized follow-up of these high-risk babies with particular attention to those who may need evaluation and intervention. Whereas, identification of the low risk group allows for a less intense bilirubin follow-up and in whom a visual check by an experienced care-provider may suffice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11105424     DOI: 10.1007/bf02723931

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  8 in total

1.  Jaundice in healthy, term neonates: do we need new action levels or new approaches?

Authors:  A K Brown; D S Seidman; D K Stevenson
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

2.  Yet another expert opinion on bilirubin toxicity.

Authors:  L Johnson
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

3.  Hyperbilirubinemia: should we adopt a new standard of care?

Authors:  W J Cashore
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

4.  Hospital stay for healthy term newborns. American Academy of Pediatrics Committee on Fetus and Newborn.

Authors: 
Journal:  Pediatrics       Date:  1995-10       Impact factor: 7.124

5.  Kernicterus in a full-term infant: the need for increased vigilance.

Authors:  W Moneit
Journal:  Pediatrics       Date:  1995-05       Impact factor: 7.124

Review 6.  Bilirubin metabolism and kernicterus.

Authors:  G R Gourley
Journal:  Adv Pediatr       Date:  1997

Review 7.  Guidelines for management of the jaundiced term and near-term infant.

Authors:  L Johnson; V K Bhutani
Journal:  Clin Perinatol       Date:  1998-09       Impact factor: 3.430

8.  Kernicterus in otherwise healthy, breast-fed term newborns.

Authors:  M J Maisels; T B Newman
Journal:  Pediatrics       Date:  1995-10       Impact factor: 7.124

  8 in total
  2 in total

1.  Can haptoglobin be an indicator for the early diagnosis of neonatal jaundice?

Authors:  Alpay Cakmak; Mustafa Calik; Ali Atas; Ibrahim Hirfanoglu; Ozcan Erel
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

2.  Value of twelfth hour bilirubin level in predicting significant hyperbilirubinemia in preterm infants.

Authors:  Izi Mayer; Tugba Gursoy; Mutlu Hayran; Secil Ercin; Fahri Ovali
Journal:  J Clin Med Res       Date:  2014-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.